Biodesix, Bio-Rad file for emergency authorization of coronavirus test

By LabPulse.com staff writers

March 20, 2020 -- Biodesix and Bio-Rad Laboratories have submitted an emergency use authorization (EUA) application with the U.S. Food and Drug Administration for their Droplet Digital polymerase chain reaction (ddPCR) test for the novel coronavirus.

Two studies conducted in China, which were published in March but have not been peer reviewed, showed that the test is effective for detecting SARS-CoV-2, the virus that causes COVID-19, and is a good complement for standard testing, helping to reduce the number of false-negative results, according to the companies.

The partners plan to evaluate the test in the U.S. after they receive an EUA.

So far, so good for pregnant women with SARS-CoV-2
Early reports from China suggest that pregnant women who have the novel coronavirus are not experiencing worse outcomes or passing the infection on to...
ACLA to Congress: Labs should not bear burden of 'free' testing
The American Clinical Laboratory Association (ACLA) has asked the U.S. Congress for a $5 billion emergency fund to cover novel coronavirus testing,...
FDA updates FAQs for coronavirus diagnostic testing
The U.S. Food and Drug Administration (FDA) has updated its set of frequently asked questions (FAQs) that serve as guidelines for clinical labs that are...
Bio-Rad debuts guide to improve access to COVID-19 tests
Bio-Rad Laboratories has launched a standard for SARS-CoV-2 to help labs validate assays and speed up access to testing for COVID-19 novel coronavirus...
Biodesix expands lung cancer blood testing portfolio
Lung cancer diagnostics firm Biodesix has introduced Nodify CDT, a blood-based test kit designed to help identify patients with lung nodules that are...

Copyright © 2020 LabPulse.com

Last Updated np 3/20/2020 12:47:18 PM



Subscribe Today
Do you want to be a Microbiology Insider?

When LabPulse gets hot new information, our Insiders are the first to find out. Stay current in today's competitive market by receiving our exclusive free email updates.

Yes, Keep Me Current